Table 2 Clinical findings in patients with or without therapy-related myeloid neoplasms

	Without therapy-related myeloid neoplasm	With therapy-related myeloid neoplasm	P
Total number	71 (77%)	21 (23%)
Age^a (years)	64 (42–89)	63 (50–81)	0.6940
Gender (Male/Female)	61/10	17/4	0.1668
Bone marrow involvement^b	Yes (29)	Yes (5)	0.2017
	No (42)	No (16)
Cytotoxic therapy
Chemotherapy	70	20
FCR	26	4
CHOP+/-R	17	8
Hyper-CVAD	6	1
Common therapy for myeloma^c	14	1
Others	7	6
Plus radiation	10	6
Plus stem cell transplant	31	7
Plus radiation, stem cell transplant	10	0
Radiation only	1	1
White blood cell count (x10⁹ /l)	5.2 (1.8–39.2)	4.2 (1.3–26.4)	0.5432
Hemoglobin (g/dl)	13.2 (9.2–17.4)	11.2 (8.7–15.1)	0.0135
Platelet count ( × 10⁹ /l)	137 (52–480)	105 (24–765)	0.7958
Total follow-up^d (months)	100 (8–307)	120 (19–255)	0.2742
Follow-up after del(20q) detection	22 (1–118)	24 (2–183)	0.8514
Overall survival^e (median, months)	86	24	0.0036
Outcomes
Died	25 (35%)	18 (86%)	<0.0001
Alive with disease	18 (25%)	3 (14%)
Alive with remission	28 (40%)	0 (0%)

Abbreviations: CHOP+/−R: Cytoxan, Adriamycin, vincristine, and prednisone with or without rituximab; FCR: fludarabine, cytoxan and rituximab; hyper-CVAD: hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone alternating with high-dose methotrexate and cytarabine.
Data presented as median (range) or number (percent).
^aAge: at the time of del(20q) detection.
^bBone marrow involvement: involvement with primary cancer at the time of del(20q) detection.
^cCommon therapeutic regimens for plasma cell myeloma include bortezomib, revlimid, desamethasone, and thalidomide.
^dTotal follow-up: time from initial diagnosis of primary cancer to last follow-up or death.
^eOverall survival: after del(20q) detection.

Search